Primary care firm knownwell joins LillyDirect to offer weight-management services
April 2 (Reuters) - Primary care company knownwell said on Wednesday it will provide health and weight-management services on Eli Lilly's (LLY.N), opens new tab direct-to-consumer online healthcare platform, LillyDirect.
Patients on LillyDirect will have access to physicians from knownwell for personalized services, knownwell said.
The company offers in-person and virtual primary care, nutrition counseling and behavioral health services, covered through patients' insurance.
Eli Lilly last month expanded its LillyDirect platform to include telehealth providers to diagnose and care for patients with Alzheimer's disease.
Telehealth firms have been partnering with LillyDirect to offer Lilly's weight-loss drug, Zepbound.
These companies have been on the lookout for an avenue to sell highly popular weight-loss drugs, as the compounded drugs industry faces increasing restrictions on making copies of the treatments.
While Zepbound and rival Novo Nordisk's (NOVOb.CO), opens new tab Wegovy were in shortage, several telehealth firms sold the drugs' cheaper copies.
The branded drugs have since been removed from the U.S. Food and Drug Administration's shortage list.
"LillyDirect continues to expand our listing of independent care provider options to benefit patients," Lilly said in an emailed statement.
The drugmaker added that "LillyDirect continues to evaluate additional independent care providers for inclusion in an effort to improve patient choice and access to quality care."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Glasgow Times
3 hours ago
- Glasgow Times
Why am I not losing weight on Mounjaro, ask a fifth of users
While many have found GLP-1 treatments to help shed pounds quickly, others have reported struggling, with around a fifth not losing the weight they'd expected. Weight loss plateaus are common, but in many cases, the reasons are identifiable and fixable, say doctors. The new weight management medication 'Tirzepatide' (brand name Mounjaro®) is shortly being made available to NHS patients to support weight loss. Access is prioritised for those with the greatest clinical need. You can find out more at: — NHS Cheshire and Merseyside (@NHSCandM) June 24, 2025 'While Mounjaro is an effective medication for weight loss, it's normal to encounter a plateau at some point," says Dr. Crystal Wyllie from online health service Zava. "To enhance your results, it's important to follow the prescribed dosing schedule and aim to reach the appropriate maintenance dose, as higher doses are generally associated with greater benefits. However, if you're experiencing side effects, it's perfectly acceptable to step up more slowly. "Your GP may recommend staying on a lower dose for longer until your body adjusts, comfort and tolerability should always guide the pace of titration. "Beyond medication, factors like maintaining a balanced diet, regular physical activity, managing stress, and getting enough sleep play a vital role in supporting your weight loss journey. If progress stalls despite these efforts, consulting your healthcare provider is essential to evaluate your plan and make necessary adjustments. "For individuals who find Mounjaro less effective or unsuitable, there are several other weight loss medications to consider. Injectable options like Wegovy and Nevolat work similarly by curbing appetite, while oral medications such as Orlistat, Xenical, and the over-the-counter Alli provide different mechanisms to support weight loss. Each treatment has unique advantages and considerations, so working closely with your doctor ensures you receive the safest and most personalised approach to achieve your goals.' Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: — We are Primary Care (@PrimaryCareNHS) June 27, 2025 Zava say there are the most common reasons the weight loss injection Mounjaro may not be working as expected, and what you can do to get back on track. Incorrect medication use or dosage Mounjaro's effectiveness often increases as you move up the dosage ladder. The medication is typically titrated slowly to reduce side effects, eventually reaching maintenance doses of up to 15mg per week. If you're still on a lower dose or haven't advanced as recommended, your weight loss may be limited. Consistency is crucial. Skipping doses, delaying titration, or not following your provider's schedule can reduce the medication's impact. Many people don't feel the full effect until 8–12 weeks in, so patience and adherence are key. You should give Mounjaro at least three months before judging its effectiveness. If you're experiencing side effects, it's absolutely fine to remain at a lower dose for longer. ZAVA healthcare providers advise stepping up more slowly if you're not tolerating side effects well, there's no need to push through discomfort. You can always increase the dose later once your body has adjusted. Comfort and tolerability are just as important as consistency for long-term success. Poor diet and lack of exercise While Mounjaro helps reduce appetite, it doesn't override the fundamental rule of weight loss: you must burn more calories than you consume. Even with a smaller appetite, eating more than your body needs will still cause progress to stall. To maintain an effective calorie deficit for weight loss, men are generally advised to consume around 1,900 calories per day (down from the typical 2,500), while women should aim for about 1,400 calories per day (down from around 2,000). Healthy diet tips: Be strict with calorie tracking until portion control becomes second nature Aim for a 600-calorie daily deficit to lose weight steadily Prioritise whole foods over high-sugar, high-fat processed options Follow a diet plan tailored to your needs, and explore healthy recipe ideas to stay on track Also, remember that initial weight loss may come from water, especially if you've reduced salt or started exercising. As your body adjusts, weight loss may temporarily plateau or appear to reverse. Finally, stay hydrated and limit alcohol. Alcohol can interfere with your metabolism and reduce the effectiveness of Mounjaro. 🧵Weight loss jab roll out 'positive for patients' but with implications for general practice that must be considered. Our Chair Kamila Hawthorne has featured widely in the national press and broadcast media responding to the phased roll-out of Mounjaro prescriptions by NHS… — Royal College of General Practitioners (@rcgp) June 23, 2025 Stress and sleep issues Chronic stress and poor sleep are major weight loss blockers. Stress increases cortisol, a hormone linked to fat retention, especially around the abdomen. Sleep deprivation increases ghrelin (hunger hormone) and decreases leptin (fullness hormone), making you more likely to overeat and less likely to move. You're also more impulsive and less motivated when sleep-deprived, making it harder to stick to your diet and exercise routine. As a solution, prioritise stress management techniques (like mindfulness or journaling), and aim for 7-9 hours of sleep per night. Health conditions and medications Medical issues such as PCOS, diabetes, hypothyroidism, or insulin resistance can all interfere with weight loss. Similarly, certain medications (like antidepressants or steroids) may cause weight gain or inhibit fat loss. If weight loss stalls despite doing everything right, consult your GP to rule out or address any underlying conditions. If you have a known medical condition, it's important to stay up to date with your routine reviews and inform your GP or specialist about any weight loss treatments you're using. Regular follow-up helps ensure your treatment plan remains safe and effective. More Mounjaro news... Unrealistic expectations It's natural to hope for rapid results, especially with a promising medication like Mounjaro. But weight loss is a long-term process. Initial drops (often water weight) can be misleading. Progress will slow, and that's okay. Avoid comparing yourself to others or obsessively checking the scale. Focus on consistency, not speed. Your journey is unique, and sustainable weight loss takes time. Lack of support Motivation by itself often isn't enough. Without support from those who understand your goals, the journey can feel lonely and overwhelming. Lean on friends and family who encourage you Join online communities or local support groups, including NHS-recommended programs Consider working with a dietitian or coach for personalised guidance and accountability Before beginning any weight loss treatment, please consult your GP or healthcare professional. These treatments may not be suitable for everyone.
Daily Mirror
14 hours ago
- Daily Mirror
NHS weight loss jabs might 'not be suitable' for these 5 groups
GPs will be prescribing Mounjaro to a select few people as the rollout begins, but others may need to avoid the jabs completely GPs can now prescribe Mounjaro, but only to a select group of patients who meet stringent criteria, such as having a BMI over 40 and being diagnosed with four out of five qualifying conditions. But people with other pre-existing conditions may not be able to access this weight loss drug at all. Dr Crystal Willie from ZAVA clarified that weight loss drugs "may be unsafe depending on medications you are taking or pre-existing medical conditions". This includes three specific conditions: Pancreatic disorders like pancreatitis History of thyroid cancer History of gallbladder disease Women who are pregnant, breastfeeding or planning to do either might also be advised to avoid the medication. The same goes for people on certain medications like insulin or immunosuppressants. Dr Willie told the Mirror: "You should speak to your doctor about any conditions or medications before taking any weight loss injection. Mounjaro weight loss injections can lower your blood sugar levels too much if taken in combination with sulfonylurea or insulin (other diabetes treatments). "You shouldn't take Mounjaro alongside other weight loss injections, such as Saxenda or Wegovy. This could increase the risk of serious health risks and side effects." The doctor also revealed that weight loss medication might actually not do what people think, as research from ZAVA found up to 20% of people using the GLP-1 drugs don't see the expected results or hit a weight loss plateau. There are a variety of reasons for this, including: Incorrect dosage Missing doses Not improving your diet and an inactive lifestyle Not keeping hydrated Excessive alcohol consumption Persistent stress Having a poor sleep routine Other health conditions may interfere with the effectiveness of weight loss drugs, like diabetes, hypothyroidism, insulin resistance and PCOS. Medications like antidepressants or steroids may also cause weight gain or hinder fat loss. Dr Wyllie added: "While Mounjaro is an effective medication for weight loss, it's normal to encounter a plateau at some point. To enhance your results, it's important to follow the prescribed dosing schedule and aim to reach the appropriate maintenance dose, as higher doses are generally associated with greater benefits. "Beyond medication, factors like maintaining a balanced diet, regular physical activity, managing stress, and getting enough sleep play a crucial role in supporting your weight loss journey. If progress stalls despite these efforts, consulting your healthcare provider is essential to evaluate your plan and make necessary adjustments."
Daily Mail
16 hours ago
- Daily Mail
ANNE ASHWORTH asks if it's worth investing in weight-loss drugs
There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and tycoons – including Elon Musk, Boris Johnson, Sharon Osbourne and Oprah Winfrey – who have used Ozempic or Mounjaro. In Britain, such has been the increase in uptake of these GLP-1 drugs that supermarket sales are shrinking. Sometimes this kind of coverage can have a wider message for investors. Public figures' reliance on 'fat jabs' underlines the forecast that the global market for these products could grow from the current $30billion (£22.4billion) to more than $150billion by the end of the decade, as millions seek a route out of obesity. So could you add weight to your portfolio by taking a slice of Eli Lilly, the US maker of Mounjaro, which is now being prescribed by GPs? Or should you opt for Novo Nordisk, the Danish giant that produced blockbuster brands Ozempic and Wegovy? An opportunity could lie in the weakness of shares of these ground-breaking businesses. Over the past year, Eli Lilly is down 13 per cent and Novo Nordisk has tumbled by 53 per cent. Will James, manager of the Guinness European Equity Income Fund, says: 'Novo Nordisk has been in the eye of the storm of late and its fall from grace has been impressive.' The two companies are battling not only against each other, but also with rival start-ups against a tense political background in the US. This is the largest market for weight-loss drugs, but US health secretary Robert F Kennedy Jr is not a fan. He wants to drive down the cost of all drugs. But he also believes that overeating is not the prime cause of obesity. He said: 'American kids did not suddenly get gluttonous and lazy – something is poisoning them.' Kennedy points the finger at the food companies. Although his assertions may not have any basis in fact, firms in this industry are already concerned about the impact of fat jabs on eating habits. The consultancy company Kantar says that lower supermarket sales have coincided with increased uptake of GLP-1 treatments. A year ago, 2.3 per cent of UK households had one member using GLP-1. It now stands at 4.1 per cent. NOVO NORDISK A bet on Novo Nordisk is a gamble on a corporate comeback. Almost exactly a year ago, the shares – priced in DKK, or Danish krone – were at their peak of Kr.1,208, against Kr.441. The pharmaceutical giant, set up a century ago, was greater in size than the Danish economy, and had become what James describes as 'the flag bearer for Europe's sometimes-doubted ability to innovate'. Today, Novo Nordisk looks more vulnerable than all-conquering. So much so that the activist hedge fund Parvus Asset Management has been amassing a stake, presumably to force a shake-up. Also pressing for change is the largest shareholder, the Novo Foundation. This follows the unseating in May of Novo Nordisk's chief executive Lars Fruergaard Jorgensen, only the fifth person to have held this role in the company's history. His departure was spurred by Eli Lilly's rapid seizure of market share in the US, where Mounjaro is the most-prescribed drug. Novo Nordisk remains the global leader, however. The problems began last year when Novo Nordisk could not satisfy demand for its drugs, leading to a damaging surge in 'compounding'. Under this arrangement, pharmacies can mix cheap copycat versions of drugs: the customers of US online telehealth companies, such as Hims & Hers Health, proved to be more than keen on 'Ozempic dupes'. The situation was exacerbated by the poor performance in a trial of new weight-loss treatment CagriSema. But Novo Nordisk is trying to shift the perception of the drug with its additional cardiovascular benefits. Meanwhile, Amycretin, another new-generation drug, appears to be delivering results superior to Mounjaro. Amycretin is administered as a once-weekly injection and a daily pill. A few months ago there may have been speculation that Novo Nordisk could turn out to be the pharmaceutical equivalent of MySpace – the pre-eminent social media site that sank into obscurity when Facebook emerged. However, in recent weeks the pessimism surrounding the company has lessened. James says: 'This is a high-quality, high-return business with an impressive track record of success and improving people's lives.' The shares are on a p/e ratio (a guide to value) of 17 times earnings. At the height of Novo Nordisk's hype, this was 40 times. This upbeat assessment is shared by brokers. In the past few days, Barclays, Deutsche, JP Morgan and UBS have reiterated their 'buy' recommendations. ELI LILLY Eli Lilly might be best known for Mounjaro, but its pipeline includes cancer and diabetes drugs and products for Alzheimer's and Crohn's disease. Established in 1876, it has also just snapped up the gene-editing start-up Verve Therapeutics for $1.3billion as a way to expand beyond weight-loss drugs, while making the most of its expertise in this area. If approval is forthcoming, Eli Lilly plans to launch Orforglipron, a once-a-day pill, next year. This represents considerable progress for a business once most-closely associated with the anxiety medication Prozac, which is no longer manufactured. The scope of Eli Lilly's range evidently inspires confidence, since 17 of the 29 analysts that follow the company rate the shares a buy with an average target price of $951, against the current $780. Putting some money into Eli Lilly and Novo Nordisk makes sense if you are diversifying your portfolio this summer and want to invest in innovation. However, both Novo Nordisk and Eli Lilly face huge competition, with about 150 rival products in development. Not all are guaranteed immediate success. This week, for example, shares in the US pharmaceutical company Amgen slipped by 6 per cent on news that its MariTide weight-loss injectable caused vomiting. Novo Nordisk is one of the top ten holdings at the giant Fundsmith fund. However, its portfolio no longer includes the drinks group Diageo, in a wider shift triggered by the impact of weight-loss drugs. Companies such as Associated British Foods, McDonald's, Mondelez, Nestle, PepsiCo, Tate & Lyle and Unilever are aware of the need to adapt as consumers move away from alcohol, confectionery, fizzy drinks and snacks. They must shape up for the fat-jab age – or face investors' ire.
